Astrazeneca Pharma India Ltd News Today

The approval is for two dosing forms: 120 mg/2.4 ml and 500 mg/10 ml.

The company may import the powder form of sodium zirconium cyclosilicate for preparation of oral suspension as Lokelma in 5 g and 10 g formulation.

As per the reported property consultants, the company has issued a global mandate for selecting candidates for the said land deal.

It is used with Durvalumab to treat advanced or recurrent endometrial cancer in patients whose disease has not progressed after first-line treatment.

This combination drug is used to treat chronic obstructive pulmonary disease (COPD) in adults, relieving symptoms and preventing exacerbations.

For the first half (H1) of FY25, the revenue rose to ₹795.5 Crore, driven by growth in oncology, biopharmaceuticals, and rare disease segments.

The company plans to launch Durvalumab in 120 mg/2.4 mL and 500 mg/10 mL solutions in India, pending statutory approvals.

The said indication is for the use of durvalumab in combination with chemotherapy as a neoadjuvant treatment.

Here are some of the stocks that may see significant price movement today: Punjab National Bank, NTPC, Power Grid, etc.

The plan to reduce the GST on these drugs aims to significantly reduce the overall cost of cancer treatment.